Pfizer (PFE) Tops Q1 EPS by 24c; offers guidance
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq fall as megacap tech drags; Iran developments watched
- Oil falls 4% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Companies to add 40 million barrels of oil to US SPR after Iran war ends, energy secretary says
- China makes small dent in deflation battle as supply-demand imbalance persists
- Sanuwave cuts Q2 2026 revenue guidance amid Ultramist sales pressure
JPMorgan Reiterates Neutral Rating on Pfizer (PFE)
April 29, 2025 4:14 PM EDTJPMorgan analyst Chris Schott reiterated a Neutral rating and $30.00 price target on Pfizer (NYSE: PFE).
The analyst comments "Exiting PFEs 1Q results and our follow up with the company, we want to provide our key takeaways. On the qtr, PFE's sales came in below expectations (which is not surprising as... More
